UC

BASF and University of California, Berkeley, celebrate their successful 10-year collaboration

Retrieved on: 
Tuesday, April 23, 2024
Stanford University, University of Southern California, University, University of California, Irvine, BASF, Research, Partnership, University of California, History, AFL–CIO, Patent, Chemistry, University of California, Berkeley, Ministry of Energy, Associate, UC, California Institute of Technology

The multidisciplinary research center is focused on evaluating new materials, technologies and processes that will help address key sustainability challenges.

Key Points: 
  • The multidisciplinary research center is focused on evaluating new materials, technologies and processes that will help address key sustainability challenges.
  • To mark the anniversary, BASF and CARA hosted a scientific symposium on sustainable transformation in chemistry on April 22.
  • Since 2014, the collaboration has expanded to 11 California universities, including UC Santa Barbara, UC Irvine as well as Stanford University, California Institute of Technology, and University of Southern California.
  • More than 80 faculty members and 170 postdocs/graduate students have worked with BASF and CARA, and BASF has hired 11 postdocs/students from the CARA community.

Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach

Retrieved on: 
Tuesday, April 23, 2024
Ulcerative colitis, CMO, Science, Strand Life Sciences, Machine learning, Partnership, PDE4, Therapy, Data, Patient, Biomarker, Medicine, Autoimmunity, UC

Carlsbad, CA, April 23, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced it has entered into a transformative strategic collaboration with Strand Life Sciences, a leading bioinformatics specialist, aimed at advancing precision medicine for ulcerative colitis (UC) therapy.

Key Points: 
  • The collaboration with Strand Life Sciences provides Palisade Bio access to advanced bioinformatics tools vital for understanding complex disease pathways and predicting responses to PDE4 inhibitors.
  • "Our partnership with Strand Life Sciences signifies a pivotal advancement in our mission to revolutionize UC treatment," said Dr. Mitch Jones, CMO at Palisade Bio.
  • "We are thrilled to collaborate with Palisade Bio in this transformative endeavor toward advancing precision medicine for ulcerative colitis therapy," added Ramesh Hariharan, CEO at Strand Life Sciences.
  • Palisade Bio is committed to advancing precision medicine solutions for UC and other inflammatory indications.

Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

Retrieved on: 
Tuesday, April 23, 2024
Ulcerative colitis, Cancer, Inflammation, Poster, Colitis, Journal, Disease, IBD, GI, AAI, Treatment, Conditional, Therapy, Autoimmunity, UC, Pharmaceutical industry

WATERTOWN, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL) today announced a poster presenting preclinical data characterizing conditionally-activated IL-10 INDUKINE molecules for the treatment of colitis in animal models, a novel approach leveraging its PREDATOR™ protein engineering platform, at IMMUNOLOGYTM 2024, the annual meeting of the American Association of Immunologists (AAI) taking place May 3-7 in Chicago, Illinois.

Key Points: 
  • Prolonged inflammation results in damage to the GI tract.
  • While the exact cause of IBD is unknown, autoimmune and immune-mediated factors have been shown to contribute to the severity of the disease.
  • Results highlighting Werewolf’s findings are summarized in a poster titled, “Development of Conditionally Active IL-10 INDUKINETM Molecules for the Treatment of Inflammatory Bowel Disease” (Board #B906).
  • The poster can be viewed in person on Monday, May 6, 2024, on board number B906, with Werewolf delegates present from 2:15-3:30pm to answer questions.

Peralta Community College District Seeks More Outstanding Leaders

Retrieved on: 
Saturday, April 20, 2024
Online, Education, University, San Francisco Chronicle, Learning, General counsel, Laney College, Human resources, College of Alameda, Dream, University of California, Davis, Berkeley City College, Conference, Dynamics, College, Faculty, University of California, Berkeley, Peralta Community College District, Student, Human, Merritt College, UC, Interest, Management

OAKLAND, California, April 19, 2024 (GLOBE NEWSWIRE) -- The Peralta Community College District has opened a nationwide search to find ideal candidates to fill four leadership positions that will play a pivotal role in setting the future direction of the East Bay District.

Key Points: 
  • OAKLAND, California, April 19, 2024 (GLOBE NEWSWIRE) -- The Peralta Community College District has opened a nationwide search to find ideal candidates to fill four leadership positions that will play a pivotal role in setting the future direction of the East Bay District.
  • “These roles are not simply about an opportunity for leadership, they are a unique chance to contribute to a vital educational mission that builds the foundation of opportunity for a large and incredibly diverse student population.”
    The Peralta Community College District comprises Berkeley City College, College of Alameda, Laney College, and Merritt College, all committed to providing world-class educational opportunities to one of the most diverse student bodies in the nation.
  • College of Alameda President: Lead the unique and vibrant College of Alameda, situated in the picturesque island city of Alameda.
  • Deputy Chancellor and Chief Operating Officer: A strategic and operational partner to the Chancellor in guiding the Peralta Community College District forward.

Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, April 16, 2024
SCI, FDA, Congress, American Academy, Investment, RAD, NDA, Insurance, Partnership, Research, Week, Patient, AAD, Atopic dermatitis, Arena Pharmaceuticals, Inflammation, Accounting, Annual general meeting, Asthma, Inflammatory Bowel Diseases, Type, Connect, UC, Pharmaceutical industry

Preclinical immunological characterization of rademikibart (CBP-201), a next-generation human monoclonal antibody targeting IL-4Rα, for the treatment of Th2 inflammatory diseases .

Key Points: 
  • Preclinical immunological characterization of rademikibart (CBP-201), a next-generation human monoclonal antibody targeting IL-4Rα, for the treatment of Th2 inflammatory diseases .
  • Four posters at the 2023 World Congress of Dermatology in July 2023 on data from the initial 16-week treatment period with rademikibart of the pivotal trial in China in patients with moderate-to-severe AD.
  • Connect expects to receive an update from Simcere as early as Q2 2024 on these next steps.
  • Cash, cash equivalents and short-term investments were $118.7 million as of December 31, 2023, compared with $161.9 million on December 31, 2022.

Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool

Retrieved on: 
Tuesday, April 16, 2024
LC-MS, Therapy, CMO, Patient, PDE4, Autoimmunity, UC, Fine chemical

Carlsbad, CA, April 16, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, announced today the successful completion of its analysis evaluating ex-vivo bioactivation of PALI-2108, an orally administered, locally acting colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug in development for patients affected by UC.

Key Points: 
  • These findings demonstrated that PALI-2108 exhibited efficient ex-vivo conversion into its active PDE4 inhibitor form in stool samples from both normal healthy volunteers and patients with UC.
  • The enzymatic activity in stool samples was assessed using LC-MS analysis with all stool samples meeting the target conversion rate within a 24-hour period.
  • The assessment showed PALI-2108 was converted into its active PDE4 inhibitor form at a mean rate of 90.1% with conversion steadily increasing over time.
  • "The results from this study underscore our confidence in PALI-2108 as a targeted treatment for moderate-to-severe UC," said Dr. Mitch Jones, CMO at Palisade Bio.

Wildix Appoints Industry Veteran Jason Uslan to Lead Global Sales Initiatives

Retrieved on: 
Thursday, May 2, 2024
Technology, Mobile, Wireless, Carriers and Services, Telecommunications, Business, Professional Services, Networks, Hardware, VoIP, UC, RingCentral, Interview, Communication, Growth, CSO

In this role, Uslan will report directly to Alberto Carlos Benigno, Chief Sales Officer (CSO) at Wildix.

Key Points: 
  • In this role, Uslan will report directly to Alberto Carlos Benigno, Chief Sales Officer (CSO) at Wildix.
  • This newly created role underscores Wildix's commitment to bolstering its global sales operations and accelerating growth in key markets worldwide.
  • As Vice President of Sales, Uslan will mentor Sales Country Managers and their teams, focusing on pipeline management, account-based marketing strategies and strategic growth initiatives.
  • "I am thrilled to join Wildix and contribute to a team that shares my passion for innovation and excellence," said Jason Uslan, newly appointed Vice President of Sales, Wildix.

‘Galactic 07’ Mission Launch Window Opens June 8

Retrieved on: 
Wednesday, May 1, 2024
Other Travel, Aerospace, Travel, Manufacturing, Astronaut, VMS Eve, Virgin Galactic, VMS, Purdue University, VSS, NASA, Research, 3D, Spacecraft, University of California, Berkeley, VSS Unity, Axiom Space, UC, Thermoplastic

Virgin Galactic Holdings, Inc. (NYSE: SPCE) today announced the ‘Galactic 07’ flight window will open Saturday, June 8, 2024.

Key Points: 
  • Virgin Galactic Holdings, Inc. (NYSE: SPCE) today announced the ‘Galactic 07’ flight window will open Saturday, June 8, 2024.
  • In addition, Purdue University and UC Berkeley will have autonomous payloads on board, supported by NASA’s Flight Opportunities program .
  • This mission showcases Virgin Galactic’s ability to provide a flexible microgravity research platform, benefiting further space exploration initiatives as well as innovations on Earth.
  • “Discovery and innovation are central to our mission at Virgin Galactic.

Strayer University Names Dr. Antoinette ‘Toni’ Farmer-Thompson President

Retrieved on: 
Tuesday, April 30, 2024
Primary, Secondary, Education, Communications, Other Education, Continuing, University, Public Relations, Investor Relations, Strayer University, Learning, Master of Business Administration, Outline of health sciences, Grand Canyon University, Arizona State University, Health education, Business administration, Trustee, Alpha Kappa Alpha, Artificial intelligence, Strayer, Cornell University, Stayer, Master of Education, Gender, Faculty, A.T. Still University, University of California, Berkeley, Multimedia, Student, AKA, UC, Management

Strayer University, a higher learning institution for working adults, has announced Dr. Antoinette ‘Toni’ Farmer-Thompson as its next president.

Key Points: 
  • Strayer University, a higher learning institution for working adults, has announced Dr. Antoinette ‘Toni’ Farmer-Thompson as its next president.
  • She assumed her role as president on April 30, 2024 and is the first Black woman to hold the position, following the transition of former Strayer University president Dr. Andréa Backman to chief transformation officer at Strategic Education, Inc.
    “We are pleased to have appointed and welcome Dr. Farmer-Thompson as president of Strayer University.
  • “I am honored to serve the wonderful students and faculty at Strayer University as its next president.
  • I want to thank the Strayer University Board of Trustees for entrusting me with this important responsibility,” said Dr. Farmer-Thompson.

PACCAR Elects New Directors

Retrieved on: 
Tuesday, April 30, 2024
Automotive Manufacturing, Automotive, Technology, Manufacturing, Professional Services, Trucking, Transport, General Automotive, Software, Fleet Management, Finance, Core, PCAR, University, Economics, Peterbilt, Information technology, DAF, Cornell University, PACCAR, General Motors, LNG, Intel, University of California, Berkeley, Marketing, Applied Materials, MBA, UC, Management

Mr. Pierre Breber and Mr. Brice Hill have been elected to the PACCAR Inc Board of Directors, effective July 1, 2024, according to Mark Pigott, PACCAR executive chairman.

Key Points: 
  • Mr. Pierre Breber and Mr. Brice Hill have been elected to the PACCAR Inc Board of Directors, effective July 1, 2024, according to Mark Pigott, PACCAR executive chairman.
  • “PACCAR is very pleased that Pierre Breber and Brice Hill will be joining the Board.
  • PACCAR is a global technology leader in the design, manufacture and customer support of high-quality light-, medium- and heavy-duty trucks under the Kenworth, Peterbilt and DAF nameplates.
  • PACCAR also designs and manufactures advanced powertrains, provides financial services and information technology, and distributes truck parts related to its principal business.